What is the Purpose of this Study?
The purpose of this study is to learn more about an experimental drug called AZD0486 and determine whether it will be safe, tolerable, and effective in treating B-cell acute lymphoblastic leukemia (B-ALL). AZD0486 is a bispecific antibody (laboratory-made antibody that engages T cells to B cells) intended for cancer therapy. T cells are a type of white blood cell that plays an important role in the immune system. Because AZD0486 sticks very strongly to leukemia cells, nearby T cells should specifically attack the tumor (leukemia) cells. AZD0486 will be given in treatment cycles; 1 cycle is 28 days (4 weeks) in duration. AZD0486 will be administered as an infusion into the vein.
Eligibility
- * Age: 16 years and older (Part A), 12 years and older (Parts B and C).
- * Participants with B-cell Acute Lymphoblastic Leukemia with CD19 expression by local lab with:
- 1. Bone marrow infiltration with \>/= 5% blasts
Where can I participate?
CS Cancer at Cedars-Sinai Medical Center : Emilie Douine-Barthelemy
More about this Clinical Trial
What is the full name of this clinical trial?
D7405C00001: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia^